Kyntra Bio, Inc.
KYNB
$7.91
-$0.13-1.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -37.14% | 6.35% | -78.26% | 117.53% | 200.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.14% | 6.35% | -78.26% | 117.53% | 200.41% |
| Cost of Revenue | -52.63% | -68.65% | -81.81% | -75.95% | -72.17% |
| Gross Profit | 54.90% | 75.47% | 82.84% | 85.41% | 76.56% |
| SG&A Expenses | -15.81% | -37.47% | -43.83% | -20.95% | -37.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.22% | -58.46% | -71.50% | -65.78% | -65.13% |
| Operating Income | 39.40% | 62.32% | 70.18% | 75.80% | 68.85% |
| Income Before Tax | 64.66% | 53.21% | 61.99% | 78.17% | 65.70% |
| Income Tax Expenses | 98.82% | 66.42% | 66.54% | 80.27% | 76.71% |
| Earnings from Continuing Operations | 64.63% | 53.18% | 61.98% | 78.17% | 65.69% |
| Earnings from Discontinued Operations | 150.89% | 98.70% | 129.02% | 239.68% | 79.04% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8,966.99% | 1,735.01% | 485.57% | 277.07% | 98.77% |
| EBIT | 39.40% | 62.32% | 70.18% | 75.80% | 68.85% |
| EBITDA | 38.44% | 61.97% | 70.15% | 75.83% | 68.78% |
| EPS Basic | 8,771.76% | 1,696.65% | 478.03% | 273.95% | 98.77% |
| Normalized Basic EPS | 37.94% | 59.82% | 67.38% | 73.95% | 67.56% |
| EPS Diluted | 8,771.76% | 1,696.65% | 478.03% | 273.95% | 98.77% |
| Normalized Diluted EPS | 37.94% | 59.82% | 67.38% | 73.95% | 67.56% |
| Average Basic Shares Outstanding | 0.31% | 0.58% | 1.02% | 1.84% | 2.28% |
| Average Diluted Shares Outstanding | 0.31% | 0.58% | 1.02% | 1.84% | 2.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |